Boardroom Alpha
Meeting calendar
NOVT · Annual meeting · Thursday, May 28, 2026

Novanta Inc

9 nominees · 4 ballot items.

Elect nine directors; advisory approval of executive compensation (say-on-pay); appoint Deloitte & Touche LLP as independent registered public accounting firm; consider other business as may properly come before the meeting.

Market cap
$5.3B
1Y TSR
+21.9%
Board grade
B-
Record date
Apr 14, 2026
Filing
DEF 14A
Meeting concluded · May 28, 2026

Follow how the vote landed and what changed on Novanta Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot4

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Elect nine nominees (Lonny J. Carpenter; Matthew T. Farrell; Matthijs Glastra; R. Matthew Johnson; Mary Katherine Ladone; Maxine L. Mauricio; Thomas N. Secor; Darlene J.S. Solomon, Ph.D.; Frank A. Wilson) to the Board of Directors until the next annual meeting.

  2. 2

    Advisory Vote on the Company’s Executive Compensation

    ManagementBoard: FOR

    Advisory (non-binding) approval of the compensation of the named executive officers as disclosed in the proxy statement (say-on-pay).

  3. 3

    Appointment of Independent Registered Public Accounting Firm

    ManagementBoard: FOR

    Appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm to serve until the 2027 annual meeting of shareholders.

  4. 4

    Other Business

    Management

    Transaction of such other business as may properly come before the meeting.

Director elections

Nominees on the ballot9

Independent
Tenure on this board
8.2 yrs
Also a director at
Merit Medical Systems Inc (MMSI)
Independent
Tenure on this board
0.7 yrs
Also a director at
Elf Beauty Inc (ELF)
Not independent
Tenure on this board
9.9 yrs
Also a director at
Idex Corp (IEX)
Independent
Tenure on this board
2.2 yrs
Also a director at
Silicon Laboratories Inc (SLAB)
Independent
Tenure on this board
2.0 yrs
Also a director at
Bioventus Inc (BVS)Inogen Inc (INGN)Kestra Medical Technologies Ltd (KMTS)
Independent
Tenure on this board
5.2 yrs
Also a director at
Cabot Corp (CBT)Alkermes PLC (ALKS)
Ownership

Top institutional holders10

Latest 13F quarter
1BlackRock, Inc.8.0%2,840,243$335M
2VANGUARD PORTFOLIO MANAGEMENT LLC7.0%2,476,881$293M
3Allspring Global Investments Holdings, LLC4.9%1,757,010$208M
4PRICE T ROWE ASSOCIATES INC /MD/4.9%1,738,905$205M
5VANGUARD CAPITAL MANAGEMENT LLC4.5%1,613,215$191M
6Conestoga Capital Advisors, LLC4.1%1,449,815$171M
7STATE STREET CORP3.8%1,339,164$158M
8BlackRock, Inc.3.3%1,165,427$138M
9WASATCH ADVISORS LP2.8%996,645$118M
10BAMCO INC /NY/2.6%915,083$108M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Novanta Inc 2026 annual meeting?
Novanta Inc (NOVT) holds its 2026 annual shareholder meeting on Thursday, May 28, 2026.
What is the record date for the Novanta Inc 2026 meeting?
The record date for the Novanta Inc 2026 meeting is Tuesday, April 14, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Novanta Inc's 2026 meeting?
The board is presenting 9 director nominees at the Novanta Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Novanta Inc 2026 meeting?
Shareholders will vote on 4 proposals at the Novanta Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer